These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 17565249)

  • 1. [Second-line chemotherapy in gastric cancer following S-1 with CPT-11 chemotherapy performed as clinical trial].
    Inokuchi M; Yamashita T; Yamada H; Kojima K; Sekita Y; Kawano T; Sugihara K
    Gan To Kagaku Ryoho; 2007 Jun; 34(6):875-9. PubMed ID: 17565249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective evaluation of sequential outpatient chemotherapy for advanced gastric cancer.
    Satoh S; Kawashima K; Matsumoto S; Hasegawa S; Okabe H; Nomura A; Yoshibayashi H; Watanabe G; Nagayama S; Fukushima M; Sakai Y
    Chemotherapy; 2007; 53(3):226-32. PubMed ID: 17356271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.
    Nishikawa K; Fujitani K; Inagaki H; Akamaru Y; Tokunaga S; Takagi M; Tamura S; Sugimoto N; Shigematsu T; Yoshikawa T; Ishiguro T; Nakamura M; Morita S; Miyashita Y; Tsuburaya A; Sakamoto J; Tsujinaka T
    Eur J Cancer; 2015 May; 51(7):808-16. PubMed ID: 25797356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility study of biweekly CPT-11 plus CDDP for S-1- and paclitaxel-refractory, metastatic gastric cancer.
    Yoshida T; Yoshikawa T; Tsuburaya A; Kobayashi O; Hasegawa S; Osaragi T; Sairenji M
    Anticancer Res; 2006; 26(2B):1595-8. PubMed ID: 16619577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Retrospective analysis of generalized chemotherapy for unresectable advanced gastric cancer].
    Miura T; Nakamura J; Yamada S; Nakazawa Y; Ozeki Y; Miura T; Yanagi M; Takahashi T
    Gan To Kagaku Ryoho; 2010 Jan; 37(1):77-81. PubMed ID: 20087036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irinotecan as the key chemotherapeutic agent in second-line treatment of metastatic gastric cancer after failure of first-line S-1 or S-1/CDDP therapy.
    Goto A; Sukawa Y; Igarashi H; Onodera K; Aoki Y; Suzuki K; Yonezawa K; Yawata A; Kobayashi T; Kaneto H; Shimizu H; Wakasugi H; Matsunaga Y; Itoh M; Okuda H; Arimura Y; Shinomura Y
    Gan To Kagaku Ryoho; 2011 Sep; 38(9):1461-6. PubMed ID: 21945893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402).
    Sugimoto N; Fujitani K; Imamura H; Uedo N; Iijima S; Imano M; Shimokawa T; Kurokawa Y; Furukawa H; Goto M
    Anticancer Res; 2014 Feb; 34(2):851-7. PubMed ID: 24511022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Results of chemotherapy using new anti-cancer drugs since S-1 for advanced or recurrent gastric cancer in our institute].
    Sato T; Kikuchi Y; Saito T; Hirano S; Kouzuma T
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1819-25. PubMed ID: 18030016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chemotherapy for gastric cancer].
    Baba H; Kakeji Y; Oki E; Tokunaga E; Ushiro S; Watanabe M; Maehara Y
    Gan To Kagaku Ryoho; 2003 Nov; 30(12):1881-8. PubMed ID: 14650954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [CPT-11 combined chemotherapy for metastatic gastric cancer].
    Narahara H; Sugimoto N; Iishi H; Tatsuta M
    Gan To Kagaku Ryoho; 2004 Nov; 31(12):1973-7. PubMed ID: 15570923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Examination of second-line therapies following administration of low-dose TS-1+CDDP for highly-advanced gastric cancer].
    Kamata T; Furukawa H; Ishii K; Senda K; Yoshimoto K; Tajima H; Takeda T; Kanno M
    Gan To Kagaku Ryoho; 2004 Jul; 31(7):1047-50. PubMed ID: 15272583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [S-1 for gastric cancer-S-1 monotherapy and its progress].
    Shitara K; Sakata Y; Kudou T; Munakata M
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():43-51. PubMed ID: 16897971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer.
    Jiang H; Qian J; Zhao P; Zhang X; Zheng Y; Mao C; Zheng Y; Chen L; Wang Y; Mou H; Fang W; Teng L; Xu N
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):197-203. PubMed ID: 26013324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A case of advanced gastric cancer with obstructive jaundice due to multiple liver metastasis successfully treated with the following combination therapy of CPT-11 and cisplatin after combination therapy of paclitaxel and TS-1].
    Watanabe T; Uchida M; Harada K; Homma N; Ogata N; Funada R; Hasegawa K; Soga K; Shibasaki K
    Gan To Kagaku Ryoho; 2007 Apr; 34(4):605-8. PubMed ID: 17431349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Controversial issues in chemotherapy for inoperable gastric cancer].
    Koizumi W; Tanabe S; Higuchi K; Sasaki T; Nakayama N; Nagaba S; Kitamura T; Azuma M; Saigenji K
    Gan To Kagaku Ryoho; 2003 Sep; 30(9):1249-55. PubMed ID: 14518402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A case of long-term survival of unresectable-advanced gastric cancer due to chemotherapy].
    Kita K; Takahashi M; Nakano S; Akabane H; Yanagida N; Shomura H; Hanamoto T; Kuji M; Oikawa F; Miyagi H
    Gan To Kagaku Ryoho; 2009 Nov; 36(12):2281-3. PubMed ID: 20037396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of weekly paclitaxel following fixed three cycles of S-1-based chemotherapy for advanced gastric cancer.
    Ohashi M; Kanda T; Kobayashi T; Hirota M; Hayami M; Yajima K; Matsuki A; Kosugi S; Hatakeyama K;
    Hepatogastroenterology; 2011; 58(106):652-8. PubMed ID: 21674889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05).
    Tanabe K; Fujii M; Nishikawa K; Kunisaki C; Tsuji A; Matsuhashi N; Takagane A; Ohno T; Kawase T; Kochi M; Yoshida K; Kakeji Y; Ichikawa W; Chin K; Terashima M; Takeuchi M; Nakajima T
    Ann Oncol; 2015 Sep; 26(9):1916-1922. PubMed ID: 26109630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chemotherapy for patients with advanced/recurrent gastric cancer and the practice at our institute].
    Kishimoto T; Imamura H; Furukawa H; Yamamoto K; Tatsuta M
    Gan To Kagaku Ryoho; 2005 Oct; 32(11):1682-4. PubMed ID: 16315908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chemotherapy in advanced gastric cancer--to ensure timely and appropriate switch to subsequent treatment options].
    Yamaguchi K; Shimamura T; Ishikubo T; Fujino K; Tada M
    Gan To Kagaku Ryoho; 2007 Jan; 34(1):29-34. PubMed ID: 17220666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.